as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹22.86
Change
-0.43 (-1.85%)
Open
₹23.17
Prev. Close
₹23.29
Day High
₹23.27
Day Low
₹22.6
Volume Analysis
Traded
370,232
Delivered
210,096
Delivery %
56.75%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Promoter holding is rising
Weaknesses (2)
- •Low return on equity (8.91%)
- •Below-average fundamentals quality score (41/100)
Opportunities (1)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹23.89 | ₹23.58 | ₹23.22 | ₹22.91 | ₹22.55 | ₹22.24 | ₹21.88 |
| Fibonacci | ₹23.58 | ₹23.32 | ₹23.17 | ₹22.91 | ₹22.65 | ₹22.5 | ₹22.24 |
| Camarilla | ₹23.04 | ₹22.98 | ₹22.92 | ₹22.91 | ₹22.8 | ₹22.74 | ₹22.68 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-44.81%
1 Week
-9.68%
1 Month
-9.03%
3 Months
-40.06%
6 Months
-37.34%
1 Year
-46.76%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Company Overview
Sector
Healthcare
Market Cap
₹1,642 Cr
P/E (TTM)
144.0
ROE
8.91%
Book Value
₹6.67
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.
TopFund Analysis
Fischer Medical Venture L scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 41/100. The strongest factor is Financial Strength (100/100), while Growth (0/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; low return on equity (8.91%); below-average fundamentals quality score (41/100). FII holding has been rising.
TopFund Score — Fundamentals Quality
41/100 — WeakData confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is expected to give good quarter
- +Promoter holding has increased by 0.94% over last quarter.
- −Stock is trading at 3.55 times its book value
- −Company has a low return on equity of 5.74% over last 3 years.
- −Company has high debtors of 342 days.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
On 14 Nov 2026, board approved Q2 FY27 results and allotted 4.417 crore shares via warrant conversion for ₹77.5 crore.
Monitoring agency report for quarter ended September 30, 2026 shows nil deviation in preferential issue proceeds.
Newspaper advertisement regarding special window for relodgement of share transfer request
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 0 | 21 | 10 | 40 | 12 | 49 | 23 | 86 | 101 | 98 | 82 | 107 |
| Expenses + | 0 | 18 | 10 | 39 | 11 | 47 | 19 | 70 | 80 | 101 | 71 | 99 |
| Operating Profit | 0 | 3 | 0 | 1 | 0 | 3 | 4 | 16 | 22 | -4 | 11 | 9 |
| OPM % | — | 12.07% | -2.08% | 1.26% | 3.15% | 5.1% | 17.02% | 18.74% | 21.34% | -3.87% | 13.73% | 8.32% |
| Other Income + | 0 | 0 | 1 | 0 | 0 | 0 | 7 | 2 | 1 | 1 | 1 | 5 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 4 | 4 | 3 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 3 | 0 | 0 | 0 | 2 | 10 | 17 | 21 | -8 | 8 | 9 |
| Tax % | — | 6.18% | 271.43% | -38.1% | 350.0% | 26.04% | 51.55% | 19.51% | 9.18% | 64.03% | 51.6% | 90.86% |
| Net Profit + | 0 | 3 | 0 | 0 | 0 | 1 | 5 | 14 | 19 | -12 | 4 | 1 |
| EPS in Rs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | — | — | — | — | — | 137 | 132 | 118 | 760 | 98 | 249 | 25 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 111 | 308 | 388 |
| Expenses + | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19 | 107 | 265 | 350 |
| Operating Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 43 | 38 |
| OPM % | -300.0% | — | — | — | — | -11.0% | -12.0% | — | 11.0% | 9.0% | 3.0% | 14.0% | 10.0% |
| Other Income + | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 12 | 8 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 11 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 4 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 47 | 30 |
| Tax % | 0.0% | 0.0% | 0.0% | — | 0.0% | 0.0% | -450.0% | 20.0% | — | 13.0% | 37.0% | 33.0% | — |
| Net Profit + | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 31 | 11 |
| EPS in Rs | 0 | 0 | 0 | 0 | 0 | 0 | 1 | -1 | 0 | 0 | 0 | 0 | 0 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 22.0% | 1.0% | — |
| Sales growth | -50 | -100 | — | — | 0 | -1,900 | -6 | -100 | — | 11,556 | 428 | 179 | 127 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | -3 | -3 | -4 | 0 | 0 | 0 | 0 | 0 | 0 | 28 | 274 | 320 | 396 |
| Borrowings + | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 85 | 107 | 85 |
| Other Liabilities + | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 34 | 179 | 199 |
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 86 | 457 | 671 | 750 |
| Fixed Assets + | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 24 | 32 | 44 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 2 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 7 | 118 | 120 |
| Other Assets + | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 70 | 425 | 519 | 584 |
| Total Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 86 | 457 | 671 | 750 |
| Equity Capital | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 54 | 64 | 65 | 70 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | -7 | -86 | -101 |
| Cash from Investing Activity + | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | -29 | -125 | -5 |
| Cash from Financing Activity + | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | 37 | 315 | 14 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | 1 | 103 | -92 |
| Free Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | -8 | -91 | 6 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -33 | 42 | 50 | 0 | 0 | -100 | 300 | 95 | — | -392 | -2,555 | -194 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 99.99% | 93.24% | 18.33% | 18.33% | 18.32% | 30.51% | 31.23% | 31.22% | 31.99% | 31.51% | 31.01% | 28.95% |
| Promoters | 0.0% | 0.0% | 74.91% | 74.91% | 74.91% | 62.82% | 61.8% | 61.8% | 61.8% | 62.15% | 62.15% | 63.09% |
| FII | 0.0% | 5.07% | 5.07% | 5.07% | 5.07% | 5.23% | 5.55% | 5.57% | 4.85% | 4.97% | 5.48% | 6.71% |
| DII | 0.0% | 1.68% | 1.68% | 1.68% | 1.68% | 1.44% | 1.42% | 1.42% | 1.36% | 1.38% | 1.35% | 1.26% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Fischer Medical Venture L (this stock) | 1,642 | 144.0 | 3.52 | 8.91% |
| Krsnaa Diagnostics Ltd | 1,661 | 16.9 | 1.6 | 10.9% |
| Tarsons Products Limited | 1,678 | 205.0 | 2.65 | 2.44% |
| Bharat Parenterals Ltd. | 1,522 | 1227.0 | 4.59 | -2.54% |
| Suraksha Diagnostic Ltd | 1,780 | 42.6 | 6.45 | 14.2% |
| Ngl Fine Chem Limited | 1,783 | 27.9 | 4.92 | 17.4% |
| Amrutajan Health Ltd | 1,461 | 71.7 | 13.58 | 20.0% |
Which Mutual Funds Hold Fischer Medical Venture L?
Frequently Asked Questions about Fischer Medical Venture L
Fischer Medical Venture L (FISCHER) closed at ₹22.86 on NSE on 19 November 2026, down 0.43 (1.85%) from the previous close.
Fischer Medical Venture L trades on the NSE (National Stock Exchange of India) under the symbol FISCHER.
Fischer Medical Venture L has a trailing twelve-month P/E (price-to-earnings) ratio of 144.0.
Fischer Medical Venture L has a dividend yield of 0.21%.
Fischer Medical Venture L's 52-week high is ₹50.5 and its 52-week low is ₹21.8.
Fischer Medical Venture L has a market capitalisation of ₹1,642 crore.
Fischer Medical Venture L has a TopFund Quality Score of 41/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Fischer Medical Venture L?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.